本发明是关于氮杂肽类新颖化合物及其医药学上可接受的盐。
This invention relates to novel compounds of the Formula Ib: that are azapeptides, and pharmaceutically acceptable salts thereof.
所公开的是式(1.0)的ERK抑制剂；及其药学上可接受的盐和溶剂合物。
Disclosed are the ERK inhibitors of Formula (1.0) : and the pharmaceutically acceptable salts and solvates thereof.
本发明使用由具体化学式表示的2- 羟基苯甲酸衍生物或其药学上可接受的盐。
The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt.
本发明涉及由右述结构式(I)表示的天冬氨酸蛋白酶抑制剂或其药学上可接受的盐。
The present invention relates to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof.
药理实验表明，此类化合物或其药学上可接受的盐对各种肿瘤细胞的增殖具有抑制作用。
Pharmacological experiment proves that the compound or relative medical acceptable salt can restrain various cancer cell proliferations.
本发明公开了6-环丙胺基-8-氯嘌呤核苷化合物包括药学上可接受的盐及其制备方法与应用。
The present invention discloses 6-cyproamino-8-chloropurine nucleoside compound, including pharmaceutically acceptable salt, its preparation method and application.
本发明提供了具有胰高血糖素受体拮抗剂活性或反向激动剂活性的、新颖的式i化合物及其药学上可接受的盐和共晶体。
The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity.
本发明提供了具有胰高血糖素受体拮抗剂活性或反向激动剂活性的、新颖的式i化合物及其药学上可接受的盐和共晶体。
The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity.
应用推荐